MGMT Methylated Glioblastoma Has a Better Prognosis
Yes, having MGMT promoter methylation in glioblastoma is definitively better—it is associated with improved survival and better response to temozolomide chemotherapy. This is one of the most clinically important biomarkers in glioblastoma management.
Why Methylation Status Matters
The MGMT (O6-methylguanine-DNA methyltransferase) gene encodes a DNA repair enzyme. When the promoter region is methylated, the gene is silenced, meaning the tumor cells cannot efficiently repair DNA damage caused by alkylating chemotherapy agents like temozolomide. This makes the cancer cells more vulnerable to treatment.
Survival Benefits with Methylation
The benefit from temozolomide is largely limited to patients with MGMT promoter-methylated glioblastoma 1. The landmark EORTC 26981-22981 trial demonstrated that while MGMT methylation was associated with longer survival overall, patients with methylated tumors appeared to derive substantially more benefit from temozolomide than those with unmethylated tumors 2.
More recent evidence confirms:
- Median overall survival is significantly higher in methylated patients: 48 months versus 22 months in unmethylated patients receiving complete resection and standard chemoradiation (P<0.001) 3
- MGMT methylation is an independent predictive factor for overall survival in multivariate analysis 3
- Patients with methylated MGMT promoters show significantly better progression-free survival after treatment: 8.9 months versus 4.6 months in unmethylated cases (P=0.016) 4
Treatment Implications
For Standard Candidates (Age <70, Good Performance Status)
The standard of care remains radiotherapy with concurrent and adjuvant temozolomide for 6 cycles, regardless of MGMT status 2, 1. However, the magnitude of benefit differs dramatically:
- Methylated tumors: Substantial benefit from temozolomide
- Unmethylated tumors: Benefit is "probably marginal" 1
For Elderly or Frail Patients
MGMT status should directly guide treatment decisions 1:
- Methylated MGMT: Treat with temozolomide alone (5 out of 28 days until progression or for 12 months)
- Unmethylated or unknown MGMT: Treat with hypofractionated radiotherapy alone
This recommendation is based on the NOA-08 and Nordic trials, which established MGMT testing as standard practice in Europe for elderly patients 1.
Important Caveats
The Controversy in Unmethylated Tumors
While the consensus until 2016 was that temozolomide could be omitted in unmethylated tumors without detriment, this has become controversial after a minor overall survival prolongation was observed with radiotherapy plus temozolomide versus radiotherapy alone in elderly patients with unmethylated glioblastomas 1. However, the benefit remains marginal.
Technical Considerations
The methylation status is not simply binary. Recent evidence suggests:
- A three-tier classification may be more appropriate: ≤8% (truly unmethylated), >8% to <11% (gray zone), ≥11% (clearly methylated) 5
- Borderline results should be reported as intermediate categories when possible 6
- The predictive value is strongest in IDH-wildtype glioblastoma and should be interpreted differently across glioma subtypes 6
Bottom Line for Clinical Practice
MGMT promoter methylation confers a significantly better prognosis in glioblastoma, with approximately double the median survival in optimally treated patients (48 vs 22 months) 3. This biomarker should be routinely tested in all glioblastoma patients, as it:
- Provides prognostic information about expected survival
- Predicts treatment response to temozolomide
- Guides treatment selection in elderly or frail patients who cannot tolerate combined modality therapy
The methylated phenotype represents a more chemotherapy-sensitive disease biology, translating directly into improved mortality and quality of life outcomes when treated appropriately with alkylating agents.